<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369340</url>
  </required_header>
  <id_info>
    <org_study_id>P3P-PK-01-CH</org_study_id>
    <nct_id>NCT03369340</nct_id>
  </id_info>
  <brief_title>Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile, Pharmacodynamics, Safety and Tolerability of Four P3P Variants in Smoking Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, crossover study to evaluate the
      pharmacokinetic (PK) profiles of four P3P variants (differing in nicotine aerosol particle
      size, nicotine concentration and in the absence or presence of a flavoring system), following
      a fixed puffing regimen and an ad libitum use period. In addition, pharmacodynamic (PD)
      effects (subjective effects and related behavioral assessments), as well as human puffing
      topography, will be evaluated, to provide further insights on product safety, acceptance, and
      use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the proposed study is to evaluate the pharmacokinetic profiles of four P3P
      variants. Variants with two different nicotine contents (1 mg/product and 2 mg/product), two
      different nicotine aersol particle sizes and presence/absence of a flavoring system will be
      tested to identify which one would yield plasma nicotine concentrations as close as possible
      to those achieved after smoking a single cigarette. All of the subjects will initially use
      the lowest nicotine content product (P3P 3). Subject will continue the study using the three
      remaining products (P3P 1, P3P 2 and P3P 4) containing 2 mg nicotine/product in a randomly
      assigned sequence.

      Two product use regimens: fixed puffing and ad libitum use will be applied to provide insight
      into nicotine absorption. The fixed puffing regimen with consistent use conditions across
      subjects will be applied in order to minimize variability. The 1 hour ad libitum use period
      will provide information on nicotine PK and product acceptance when subjects use the P3P
      according to their own puffing behavior which is closer to a real-world setting.

      Safety and tolerability will also be assessed throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A single-center, open-label, randomized, crossover study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Sponsor staff, Investigator, the subjects and the investigational site will be blinded to the randomization sequences until they are assigned. Subjects will not be informed of the complete sequence to which they have been assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Nicotine Concentration-time Profile</measure>
    <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the Maximum Nicotine Concentration [Tmax]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Start of Product Use (T0 Fix) to 4 Hours [AUCfix (0-4h)]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Nicotine Concentration-time Profile</measure>
    <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Nicotine Concentration [Cpeak]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Plasma Nicotine Concentration [Tpeak]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Nicotine Concentration [Ctrough]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of Plasma Nicotine Concentration From T0 ad Lib to 1 Hour [Caverage]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the average of plasma nicotine concentration [Caverage], of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Start of Product Use (T0 ad Lib) to 4 Hours [AUCad Lib (0-4h)]</measure>
    <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
    <description>To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Craving for a Cigarette During and After the Fixed Puffing Regimen</measure>
    <time_frame>During and up to 4 hours post-product use on days 1, 2, 3 and 4</time_frame>
    <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Craving for a Cigarette During and After the ad Libitum Use Period</measure>
    <time_frame>During and up to 4 hours post-product use on days 1, 2, 3 and 4</time_frame>
    <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Evaluation</measure>
    <time_frame>Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4</time_frame>
    <description>Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period. Assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Parameters</measure>
    <time_frame>Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4</time_frame>
    <description>Measured with a Sensory Questionnaire (SQ) following the ad libitum use period. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the Fixed Puffing Regimen Period.</measure>
    <time_frame>During fixed puffing product use on days 1, 2, 3 and 4</time_frame>
    <description>Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the fixed puffing regimen period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the ad Libitum Use Period.</measure>
    <time_frame>During ad libitum product use on days 1, 2, 3 and 4</time_frame>
    <description>Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the ad libitum use period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Powder Aerosolized From P3P From the Fixed Puffing Regimen.</measure>
    <time_frame>Before and after fixed puffing product use on days 1, 2, 3 and 4</time_frame>
    <description>Descriptive statistics of P3P weight before use, and after use, for the fixed puffing regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Powder Aerosolized From P3P From the ad Libitum Use Period (Per Product Used).</measure>
    <time_frame>Before and after ad libitum product use on days 1, 2, 3 and 4</time_frame>
    <description>P3P weight before use, and after use, to determine the amount of powder aerosolized from P3P during Ad Libitum use (per product used).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 1</intervention_name>
    <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 2</intervention_name>
    <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 3</intervention_name>
    <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P 4</intervention_name>
    <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
    <arm_group_label>Product Sequence 1</arm_group_label>
    <arm_group_label>Product Sequence 2</arm_group_label>
    <arm_group_label>Product Sequence 3</arm_group_label>
    <arm_group_label>Product Sequence 4</arm_group_label>
    <arm_group_label>Product Sequence 5</arm_group_label>
    <arm_group_label>Product Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject has signed the Informed Consent Form (ICF) and is able to understand the
             information provided in the ICF.

          -  Subject is between 21 and 65 years old.

          -  Subject is Caucasian.

          -  Smoking, healthy subject as judged by the Investigator or designee based on available
             assessments from the screening period.

          -  Subject has been smoking at least 10 commercially available cigarettes per day at
             least for the last 4 weeks prior to Screening Visit. Smoking status will be verified
             based on a urinary cotinine test (cotinine ≥ 200 ng/mL).

          -  Subject has been smoking for at least the last 3 years prior to Screening Visit.

          -  Subject does not plan to quit smoking in the next 2 months after the Screening Visit.

        Exclusion criteria:

          -  Female subject is pregnant or breastfeeding.

          -  Female subject uses estrogen-containing hormonal contraception or hormone replacement
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milko Radicioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CROSS Research, Arzo, Ticino, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CROSS Research</name>
      <address>
        <city>Arzo</city>
        <state>Ticino</state>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <results_first_submitted>May 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2020</results_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Nicotine-containing product</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03369340/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03369340/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>40 subjects were screened for eligibility. 21 subjects were screen failures (10 reserve subjects were not enrolled, 9 subjects did not meet eligibility criteria, and 2 subjects withdrew.)</recruitment_details>
      <pre_assignment_details>On Day 1, 19 subjects were enrolled and exposed to “P3P 3” before randomization.
One enrolled subject withdrew after P3P 3 use before randomization. 18 subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Product Sequence 1</title>
          <description>Subjects will follow a sequence of product exposure comprised of:
P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4</description>
        </group>
        <group group_id="P2">
          <title>Product Sequence 2</title>
          <description>Subjects will be follow a sequence of product exposure comprised of:
P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4</description>
        </group>
        <group group_id="P3">
          <title>Product Sequence 3</title>
          <description>Subjects will follow a sequence of product exposure comprised of:
P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4</description>
        </group>
        <group group_id="P4">
          <title>Product Sequence 4</title>
          <description>Subjects will follow a sequence of product exposure comprised of:
P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4</description>
        </group>
        <group group_id="P5">
          <title>Product Sequence 5</title>
          <description>Subjects will follow a sequence of product exposure comprised of:
P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4</description>
        </group>
        <group group_id="P6">
          <title>Product Sequence 6</title>
          <description>Subjects will follow a sequence of product exposure comprised of:
P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Day 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Safety Population</title>
          <description>The safety population comprised all enrolled subjects who were exposed to P3P during the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>centimetres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.6" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Nicotine Concentration-time Profile</title>
        <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Nicotine Concentration-time Profile</title>
          <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 mins after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.751" lower_limit="0.447" upper_limit="1.26"/>
                    <measurement group_id="O2" value="0.336" lower_limit="0.200" upper_limit="0.562"/>
                    <measurement group_id="O3" value="0.205" lower_limit="0.119" upper_limit="0.351"/>
                    <measurement group_id="O4" value="0.478" lower_limit="0.278" upper_limit="0.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 mins after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" lower_limit="1.05" upper_limit="2.32"/>
                    <measurement group_id="O2" value="0.740" lower_limit="0.489" upper_limit="1.12"/>
                    <measurement group_id="O3" value="0.394" lower_limit="0.206" upper_limit="0.756"/>
                    <measurement group_id="O4" value="1.20" lower_limit="0.762" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 mins after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" lower_limit="1.44" upper_limit="2.79"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.910" upper_limit="1.58"/>
                    <measurement group_id="O3" value="0.547" lower_limit="0.330" upper_limit="0.906"/>
                    <measurement group_id="O4" value="1.66" lower_limit="1.18" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mins after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.75" upper_limit="3.11"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.23" upper_limit="1.93"/>
                    <measurement group_id="O3" value="0.701" lower_limit="0.411" upper_limit="1.19"/>
                    <measurement group_id="O4" value="1.92" lower_limit="1.43" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 mins after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="1.92" upper_limit="3.56"/>
                    <measurement group_id="O2" value="1.78" lower_limit="1.35" upper_limit="2.35"/>
                    <measurement group_id="O3" value="0.947" lower_limit="0.661" upper_limit="1.36"/>
                    <measurement group_id="O4" value="2.31" lower_limit="1.87" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 mins after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" lower_limit="1.97" upper_limit="2.91"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.57" upper_limit="2.51"/>
                    <measurement group_id="O3" value="0.931" lower_limit="0.697" upper_limit="1.24"/>
                    <measurement group_id="O4" value="2.25" lower_limit="1.91" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.60" upper_limit="2.42"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.35" upper_limit="2.18"/>
                    <measurement group_id="O3" value="0.758" lower_limit="0.573" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.85" lower_limit="1.57" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="0.911" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.17" lower_limit="0.897" upper_limit="1.53"/>
                    <measurement group_id="O3" value="0.383" lower_limit="0.241" upper_limit="0.607"/>
                    <measurement group_id="O4" value="1.23" lower_limit="1.00" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after start of fixed puffing product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.553" lower_limit="0.391" upper_limit="0.783"/>
                    <measurement group_id="O2" value="0.568" lower_limit="0.398" upper_limit="0.812"/>
                    <measurement group_id="O3" value="0.219" lower_limit="0.146" upper_limit="0.329"/>
                    <measurement group_id="O4" value="0.623" lower_limit="0.487" upper_limit="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration [Cmax]</title>
        <description>To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration [Cmax]</title>
          <description>To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects</population>
          <units>ng/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="2.33" upper_limit="4.06"/>
                    <measurement group_id="O2" value="2.13" lower_limit="1.62" upper_limit="2.81"/>
                    <measurement group_id="O3" value="1.14" lower_limit="0.768" upper_limit="1.68"/>
                    <measurement group_id="O4" value="2.79" lower_limit="2.10" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to the Maximum Nicotine Concentration [Tmax]</title>
        <description>To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Maximum Nicotine Concentration [Tmax]</title>
          <description>To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="4.00" upper_limit="60.0"/>
                    <measurement group_id="O2" value="22.5" lower_limit="4.00" upper_limit="62.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="4.00" upper_limit="60.0"/>
                    <measurement group_id="O4" value="15.0" lower_limit="4.00" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Start of Product Use (T0 Fix) to 4 Hours [AUCfix (0-4h)]</title>
        <description>To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Start of Product Use (T0 Fix) to 4 Hours [AUCfix (0-4h)]</title>
          <description>To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL*h</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.84" lower_limit="4.56" upper_limit="7.48"/>
                    <measurement group_id="O2" value="5.08" lower_limit="3.97" upper_limit="6.50"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.67" upper_limit="3.37"/>
                    <measurement group_id="O4" value="5.73" lower_limit="4.45" upper_limit="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Nicotine Concentration-time Profile</title>
        <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Nicotine Concentration-time Profile</title>
          <description>To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="1.25" upper_limit="2.53"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.17" upper_limit="1.87"/>
                    <measurement group_id="O3" value="0.945" lower_limit="0.647" upper_limit="1.38"/>
                    <measurement group_id="O4" value="1.49" lower_limit="1.01" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.72" upper_limit="3.11"/>
                    <measurement group_id="O2" value="2.27" lower_limit="1.69" upper_limit="3.04"/>
                    <measurement group_id="O3" value="1.21" lower_limit="0.981" upper_limit="1.50"/>
                    <measurement group_id="O4" value="2.06" lower_limit="1.55" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" lower_limit="2.63" upper_limit="3.97"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.50" upper_limit="4.01"/>
                    <measurement group_id="O3" value="1.68" lower_limit="1.30" upper_limit="2.17"/>
                    <measurement group_id="O4" value="2.87" lower_limit="2.10" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 minutes after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" lower_limit="3.13" upper_limit="5.02"/>
                    <measurement group_id="O2" value="4.05" lower_limit="3.17" upper_limit="5.17"/>
                    <measurement group_id="O3" value="1.98" lower_limit="1.58" upper_limit="2.47"/>
                    <measurement group_id="O4" value="3.86" lower_limit="2.88" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" lower_limit="4.20" upper_limit="6.64"/>
                    <measurement group_id="O2" value="5.23" lower_limit="4.15" upper_limit="6.58"/>
                    <measurement group_id="O3" value="2.67" lower_limit="2.12" upper_limit="3.36"/>
                    <measurement group_id="O4" value="4.42" lower_limit="3.26" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" lower_limit="2.98" upper_limit="5.13"/>
                    <measurement group_id="O2" value="4.42" lower_limit="3.44" upper_limit="5.69"/>
                    <measurement group_id="O3" value="1.84" lower_limit="1.39" upper_limit="2.42"/>
                    <measurement group_id="O4" value="3.61" lower_limit="2.66" upper_limit="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after start of ad libitum product use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.55" upper_limit="2.77"/>
                    <measurement group_id="O2" value="2.35" lower_limit="1.71" upper_limit="3.22"/>
                    <measurement group_id="O3" value="0.917" lower_limit="0.699" upper_limit="1.20"/>
                    <measurement group_id="O4" value="1.81" lower_limit="1.38" upper_limit="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Nicotine Concentration [Cpeak]</title>
        <description>To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Nicotine Concentration [Cpeak]</title>
          <description>To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" lower_limit="4.24" upper_limit="6.84"/>
                    <measurement group_id="O2" value="5.41" lower_limit="4.26" upper_limit="6.88"/>
                    <measurement group_id="O3" value="2.63" lower_limit="1.97" upper_limit="3.52"/>
                    <measurement group_id="O4" value="4.67" lower_limit="3.67" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Plasma Nicotine Concentration [Tpeak]</title>
        <description>To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Nicotine Concentration [Tpeak]</title>
          <description>To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="22.5"/>
                    <measurement group_id="O2" value="82.4" spread="52.1"/>
                    <measurement group_id="O3" value="68.0" spread="27.2"/>
                    <measurement group_id="O4" value="61.9" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Nicotine Concentration [Ctrough]</title>
        <description>To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Nicotine Concentration [Ctrough]</title>
          <description>To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.32" upper_limit="2.45"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.16" upper_limit="2.15"/>
                    <measurement group_id="O3" value="1.13" lower_limit="0.767" upper_limit="1.67"/>
                    <measurement group_id="O4" value="1.56" lower_limit="1.14" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average of Plasma Nicotine Concentration From T0 ad Lib to 1 Hour [Caverage]</title>
        <description>To measure the average of plasma nicotine concentration [Caverage], of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels</description>
        <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Average of Plasma Nicotine Concentration From T0 ad Lib to 1 Hour [Caverage]</title>
          <description>To measure the average of plasma nicotine concentration [Caverage], of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="2.53" upper_limit="4.02"/>
                    <measurement group_id="O2" value="3.13" lower_limit="2.49" upper_limit="3.95"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.29" upper_limit="2.21"/>
                    <measurement group_id="O4" value="2.87" lower_limit="2.27" upper_limit="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Start of Product Use (T0 ad Lib) to 4 Hours [AUCad Lib (0-4h)]</title>
        <description>To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4</time_frame>
        <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Start of Product Use (T0 ad Lib) to 4 Hours [AUCad Lib (0-4h)]</title>
          <description>To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.</description>
          <population>Baseline correction of nicotine concentrations could be performed for 16 out of the 18 randomized subjects.</population>
          <units>ng/mL*h</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="10.7" upper_limit="17.3"/>
                    <measurement group_id="O2" value="14.5" lower_limit="11.4" upper_limit="18.4"/>
                    <measurement group_id="O3" value="6.32" lower_limit="4.73" upper_limit="8.44"/>
                    <measurement group_id="O4" value="12.1" lower_limit="9.54" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Craving for a Cigarette During and After the Fixed Puffing Regimen</title>
        <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).</description>
        <time_frame>During and up to 4 hours post-product use on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Craving for a Cigarette During and After the Fixed Puffing Regimen</title>
          <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).</description>
          <units>score on a scale (millimetres)*h</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="4.76" upper_limit="75.4"/>
                    <measurement group_id="O2" value="57.6" lower_limit="22.3" upper_limit="92.9"/>
                    <measurement group_id="O3" value="116" lower_limit="71.7" upper_limit="159"/>
                    <measurement group_id="O4" value="64.8" lower_limit="29.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Craving for a Cigarette During and After the ad Libitum Use Period</title>
        <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).</description>
        <time_frame>During and up to 4 hours post-product use on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Craving for a Cigarette During and After the ad Libitum Use Period</title>
          <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).</description>
          <units>score on a scale (millimetres)*h</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="36.7" upper_limit="116"/>
                    <measurement group_id="O2" value="72.4" lower_limit="32.7" upper_limit="112"/>
                    <measurement group_id="O3" value="89.6" lower_limit="46.2" upper_limit="133"/>
                    <measurement group_id="O4" value="66.8" lower_limit="27.2" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Evaluation</title>
        <description>Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period. Assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
        <time_frame>Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Product Evaluation</title>
          <description>Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period. Assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Product Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" lower_limit="2.68" upper_limit="3.76"/>
                    <measurement group_id="O2" value="4.40" lower_limit="3.86" upper_limit="4.95"/>
                    <measurement group_id="O3" value="4.42" lower_limit="3.73" upper_limit="5.11"/>
                    <measurement group_id="O4" value="4.13" lower_limit="3.58" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of Respiratory Tract Sensations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" lower_limit="2.04" upper_limit="3.17"/>
                    <measurement group_id="O2" value="3.88" lower_limit="3.32" upper_limit="4.44"/>
                    <measurement group_id="O3" value="3.75" lower_limit="3.04" upper_limit="4.46"/>
                    <measurement group_id="O4" value="3.60" lower_limit="3.04" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Reward</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" lower_limit="2.57" upper_limit="3.67"/>
                    <measurement group_id="O2" value="3.38" lower_limit="2.82" upper_limit="3.93"/>
                    <measurement group_id="O3" value="3.21" lower_limit="2.58" upper_limit="3.83"/>
                    <measurement group_id="O4" value="3.25" lower_limit="2.70" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.993" upper_limit="1.46"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.965" upper_limit="1.43"/>
                    <measurement group_id="O3" value="1.10" lower_limit="0.754" upper_limit="1.44"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.798" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving Reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" lower_limit="3.78" upper_limit="5.05"/>
                    <measurement group_id="O2" value="4.58" lower_limit="3.95" upper_limit="5.22"/>
                    <measurement group_id="O3" value="4.14" lower_limit="3.30" upper_limit="4.98"/>
                    <measurement group_id="O4" value="4.58" lower_limit="3.95" upper_limit="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Parameters</title>
        <description>Measured with a Sensory Questionnaire (SQ) following the ad libitum use period. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
        <time_frame>Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Parameters</title>
          <description>Measured with a Sensory Questionnaire (SQ) following the ad libitum use period. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Puffs Evaluation/Liking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" lower_limit="2.64" upper_limit="3.69"/>
                    <measurement group_id="O2" value="4.22" lower_limit="3.70" upper_limit="4.75"/>
                    <measurement group_id="O3" value="4.22" lower_limit="3.52" upper_limit="4.93"/>
                    <measurement group_id="O4" value="3.78" lower_limit="3.25" upper_limit="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Harshness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" lower_limit="4.11" upper_limit="5.23"/>
                    <measurement group_id="O2" value="3.61" lower_limit="3.05" upper_limit="4.17"/>
                    <measurement group_id="O3" value="3.67" lower_limit="2.87" upper_limit="4.47"/>
                    <measurement group_id="O4" value="3.72" lower_limit="3.16" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Similarity to Own Brand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="1.92" upper_limit="3.23"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.97" upper_limit="3.29"/>
                    <measurement group_id="O3" value="2.78" lower_limit="2.01" upper_limit="3.55"/>
                    <measurement group_id="O4" value="2.30" lower_limit="1.64" upper_limit="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength on Tongue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" lower_limit="2.67" upper_limit="4.20"/>
                    <measurement group_id="O2" value="3.10" lower_limit="2.34" upper_limit="3.86"/>
                    <measurement group_id="O3" value="3.53" lower_limit="2.61" upper_limit="4.44"/>
                    <measurement group_id="O4" value="2.88" lower_limit="2.12" upper_limit="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength in Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" lower_limit="1.33" upper_limit="2.45"/>
                    <measurement group_id="O2" value="1.56" lower_limit="0.995" upper_limit="2.12"/>
                    <measurement group_id="O3" value="1.89" lower_limit="1.23" upper_limit="2.55"/>
                    <measurement group_id="O4" value="1.72" lower_limit="1.16" upper_limit="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength in Back of Mouth/Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" lower_limit="3.73" upper_limit="5.07"/>
                    <measurement group_id="O2" value="3.56" lower_limit="2.90" upper_limit="4.23"/>
                    <measurement group_id="O3" value="3.69" lower_limit="2.78" upper_limit="4.61"/>
                    <measurement group_id="O4" value="3.79" lower_limit="3.12" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puff Strength in Windpipe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" lower_limit="3.72" upper_limit="5.04"/>
                    <measurement group_id="O2" value="3.44" lower_limit="2.78" upper_limit="4.09"/>
                    <measurement group_id="O3" value="3.14" lower_limit="2.25" upper_limit="4.02"/>
                    <measurement group_id="O4" value="3.77" lower_limit="3.11" upper_limit="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puff Strength in Chest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" lower_limit="2.75" upper_limit="4.21"/>
                    <measurement group_id="O2" value="2.81" lower_limit="2.09" upper_limit="3.54"/>
                    <measurement group_id="O3" value="2.39" lower_limit="1.50" upper_limit="3.28"/>
                    <measurement group_id="O4" value="3.37" lower_limit="2.64" upper_limit="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the Fixed Puffing Regimen Period.</title>
        <description>Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the fixed puffing regimen period.</description>
        <time_frame>During fixed puffing product use on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the Fixed Puffing Regimen Period.</title>
          <description>Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the fixed puffing regimen period.</description>
          <units>mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Puff Volume (per product)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="732" lower_limit="630" upper_limit="850"/>
                    <measurement group_id="O2" value="806" lower_limit="686" upper_limit="948"/>
                    <measurement group_id="O3" value="878" lower_limit="714" upper_limit="1079"/>
                    <measurement group_id="O4" value="845" lower_limit="733" upper_limit="975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Puff Volume (per product)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" lower_limit="52.5" upper_limit="70.8"/>
                    <measurement group_id="O2" value="66.9" lower_limit="56.8" upper_limit="78.8"/>
                    <measurement group_id="O3" value="72.8" lower_limit="59.7" upper_limit="88.9"/>
                    <measurement group_id="O4" value="70.4" lower_limit="61.1" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the ad Libitum Use Period.</title>
        <description>Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the ad libitum use period.</description>
        <time_frame>During ad libitum product use on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the ad Libitum Use Period.</title>
          <description>Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the ad libitum use period.</description>
          <units>mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Puff Volume (per product)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1485" lower_limit="1100" upper_limit="2006"/>
                    <measurement group_id="O2" value="1559" lower_limit="1306" upper_limit="1861"/>
                    <measurement group_id="O3" value="1598" lower_limit="1291" upper_limit="1976"/>
                    <measurement group_id="O4" value="1512" lower_limit="1177" upper_limit="1941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Puff Volume (per product)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="46.2" upper_limit="71.6"/>
                    <measurement group_id="O2" value="62.3" lower_limit="51.2" upper_limit="75.9"/>
                    <measurement group_id="O3" value="65.4" lower_limit="56.4" upper_limit="75.9"/>
                    <measurement group_id="O4" value="62.7" lower_limit="52.5" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Powder Aerosolized From P3P From the Fixed Puffing Regimen.</title>
        <description>Descriptive statistics of P3P weight before use, and after use, for the fixed puffing regimen.</description>
        <time_frame>Before and after fixed puffing product use on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Powder Aerosolized From P3P From the Fixed Puffing Regimen.</title>
          <description>Descriptive statistics of P3P weight before use, and after use, for the fixed puffing regimen.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight before use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954" spread="2.70"/>
                    <measurement group_id="O2" value="965" spread="2.11"/>
                    <measurement group_id="O3" value="966" spread="2.48"/>
                    <measurement group_id="O4" value="965" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight after use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="938" spread="6.01"/>
                    <measurement group_id="O2" value="944" spread="6.46"/>
                    <measurement group_id="O3" value="943" spread="6.46"/>
                    <measurement group_id="O4" value="942" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference of Weight (Before/After Use)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="6.16"/>
                    <measurement group_id="O2" value="21.6" spread="5.89"/>
                    <measurement group_id="O3" value="22.6" spread="6.07"/>
                    <measurement group_id="O4" value="22.2" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Powder Aerosolized From P3P From the ad Libitum Use Period (Per Product Used).</title>
        <description>P3P weight before use, and after use, to determine the amount of powder aerosolized from P3P during Ad Libitum use (per product used).</description>
        <time_frame>Before and after ad libitum product use on days 1, 2, 3 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P 1</title>
            <description>2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O2">
            <title>P3P 2</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O3">
            <title>P3P 3</title>
            <description>1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm</description>
          </group>
          <group group_id="O4">
            <title>P3P 4</title>
            <description>2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Powder Aerosolized From P3P From the ad Libitum Use Period (Per Product Used).</title>
          <description>P3P weight before use, and after use, to determine the amount of powder aerosolized from P3P during Ad Libitum use (per product used).</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average Weight before use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954" spread="1.83"/>
                    <measurement group_id="O2" value="964" spread="1.36"/>
                    <measurement group_id="O3" value="964" spread="1.94"/>
                    <measurement group_id="O4" value="964" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Weight after use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="937" spread="4.69"/>
                    <measurement group_id="O2" value="938" spread="4.90"/>
                    <measurement group_id="O3" value="939" spread="4.19"/>
                    <measurement group_id="O4" value="940" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Difference of Weight (Before/After Use)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="4.17"/>
                    <measurement group_id="O2" value="25.9" spread="4.63"/>
                    <measurement group_id="O3" value="25.6" spread="3.92"/>
                    <measurement group_id="O4" value="23.9" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the signature of the ICF by each subject until the end of the safety follow-up period, for a duration of up to 34 days for each subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Safety Population (P3P 1)</title>
          <description>Comprising enrolled subjects who were exposed to P3P 1 during the study.</description>
        </group>
        <group group_id="E2">
          <title>Safety Population (P3P 2)</title>
          <description>Comprising enrolled subjects who were exposed to P3P 2 during the study.</description>
        </group>
        <group group_id="E3">
          <title>Safety Population (P3P 3)</title>
          <description>Comprising enrolled subjects who were exposed to P3P 3 during the study.</description>
        </group>
        <group group_id="E4">
          <title>Safety Population (P3P 4)</title>
          <description>Comprising enrolled subjects who were exposed to P3P 4 during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocytes increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophils decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle Haziza, Director Health Science and Biostatistics</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 58 242 11 11</phone>
      <email>ClinicalTrials.PMI@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

